Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
Anita M LoughlinQing QiaoAnthony P NunesPeter ÖhmanStephen EzzyLaura YochumC Robin CliffordRobert GatelyDavid D DoreJohn D SeegerPublished in: Diabetes, obesity & metabolism (2018)
Regardless of age or renal function, the benefits of EQW relative to BI treatment are improved glycaemic control and increased weight loss, which should be weighed against the increased risk of gastrointestinal symptoms.
Keyphrases
- type diabetes
- weight loss
- randomized controlled trial
- bariatric surgery
- systematic review
- glycemic control
- open label
- roux en y gastric bypass
- middle aged
- stem cells
- emergency department
- gastric bypass
- clinical trial
- metabolic syndrome
- mesenchymal stem cells
- adipose tissue
- physical activity
- insulin resistance
- community dwelling
- bone marrow
- chemotherapy induced